NEW YORK, June 3, 2020 /PRNewswire/ -- Oppenheimer &
Co. Inc. ("Oppenheimer") – a leading investment bank, wealth
manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) –
today announced the expansion of its Life Sciences research team
with the addition of Frank Brisebois
as Managing Director and Senior Analyst. The appointment of Mr.
Brisebois to this position, covering Biotechnology and
Biopharmaceuticals, reflects Oppenheimer's ongoing commitment to
developing best-in-class analysis and research related to the Life
Sciences sector.
"These are dynamic times in the Life Sciences sector, with new
therapies and technological innovations poised to revolutionize
entire business models," said John
Parks, Managing Director & Director of Equity Research
at Oppenheimer. "The Life Sciences sector has historically been a
strong area of focus for Oppenheimer. Frank's experience and
insights will reinforce our Life Sciences expertise during a time
of significant change, while expanding our research offerings in
ways that strengthen and grow our Life Sciences team."
With over a decade of relevant experience, Mr. Brisebois is
based in Boston, and is focused on
the subsectors of Ophthalmology, Audiology, Pain/CNS, Cannabis
Derivatives, and Digital Medicine. Prior to joining Oppenheimer, he
was a Senior Research Analyst at Craig-Hallum Capital covering
Biotechnology and Biopharmaceuticals. He also previously worked at
Laidlaw Capital Markets for five years and started his career at
healthcare specialty firm Summer Street Research Partners. He holds
a Bachelor of Arts in Molecular Biology from Colgate University, and a Master of Science in
Pharmaceutical Sciences from the University of
Montreal.
Mr. Brisebois said, "I'm excited to join Oppenheimer's Life
Sciences research team, which has distinguished itself over the
years with its strong insights and analysis about this sector. I
look forward to partnering closely with my new colleagues to
continue to strengthen the firm's longstanding expertise in Life
Sciences."
Oppenheimer & Co. Inc.
Oppenheimer & Co.
Inc. Oppenheimer & Co. Inc. (Oppenheimer), a principal
subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock
Exchange), and its affiliates provide a full range of wealth
management, securities brokerage and investment banking services to
high net-worth individuals, families, corporate executives, local
governments, businesses and institutions.
Media Contact:
Joseph
Kuo / Michael Dugan
Haven Tower Group LLC
424 317 4851 or 424 317 4852
jkuo@haventower.com or mdugan@haventower.com
View original
content:http://www.prnewswire.com/news-releases/oppenheimer--co-inc-expands-life-sciences-research-team-with-addition-of-frank-brisebois-as-managing-director-and-senior-analyst-301069746.html
SOURCE Oppenheimer & Co. Inc.